These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30253095)

  • 1. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
    Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
    J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
    Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
    Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.
    Carlson AS; Cui H; Divakaran A; Johnson JA; Brunner RM; Pomerantz WCK; Topczewski JJ
    ACS Med Chem Lett; 2019 Sep; 10(9):1296-1301. PubMed ID: 31531200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
    Cui H; Divakaran A; Hoell ZJ; Ellingson MO; Scholtz CR; Zahid H; Johnson JA; Griffith EC; Gee CT; Lee AL; Khanal S; Shi K; Aihara H; Shah VH; Lee RE; Harki DA; Pomerantz WCK
    J Med Chem; 2022 Feb; 65(3):2342-2360. PubMed ID: 35007061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
    Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
    Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
    Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression.
    Zhou Z; Li X; Liu Z; Huang L; Yao Y; Li L; Chen J; Zhang R; Zhou J; Wang L; Zhang QQ
    Front Pharmacol; 2020; 11():1043. PubMed ID: 32765266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
    Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
    Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress and structural analyses of domain-selective BET inhibitors.
    Divakaran A; Harki DA; Pomerantz WCK
    Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A.
    Williams FP; Milbradt AG; Embrey KJ; Bobby R
    PLoS One; 2016; 11(4):e0154607. PubMed ID: 27128490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
    Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
    Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Murine Leukemia Virus Integrase-Derived Peptides That Bind Brd4 Extra-Terminal Domain as Candidates for Suppression of Acute Myeloid Leukemia.
    Xing E; Surendranathan N; Kong X; Cyberski N; Garcia JD; Cheng X; Sharma A; Li PK; Larue RC
    ACS Pharmacol Transl Sci; 2021 Oct; 4(5):1628-1638. PubMed ID: 34661079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.